CGEN logo

Compugen Ltd

CGEN

CGEN: Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

more

Show CGEN Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of CGEN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by CGEN's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Jul. 18, 2023
  • Patent Title: Anti-pvrig antibodies and methods of use Apr. 11, 2023
  • Patent Title: Triple combination antibody therapies Jan. 18, 2022
  • Patent Title: Anti-pvrig antibodies and methods of use Jan. 11, 2022
  • Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Aug. 25, 2020
  • Patent Title: Pvrig polypeptides and methods of treatment Feb. 04, 2020
  • Patent Title: Anti-pvrig antibodies and methods of use Jul. 16, 2019
  • Patent Title: Anti-pvrig antibodies and methods of use Mar. 12, 2019
  • Patent Title: Anti-tigit anibodies, anti-pvrig antibodies and combinations thereof Feb. 26, 2019
  • Patent Title: Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof Nov. 13, 2018
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Oct. 16, 2018
  • Patent Title: Anti-pvrig antibodies and methods of use Jul. 25, 2017
  • Patent Title: C10rf32 antibodies, and uses thereof for treatment of cancer Apr. 11, 2017
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Jan. 31, 2017
  • Patent Title: Heparanase splice variant Aug. 30, 2016
  • Patent Title: Polypeptides and uses thereof for treatment of autoimmune disorders and infection Aug. 30, 2016
  • Patent Title: Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer Aug. 09, 2016
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Jun. 28, 2016
  • Patent Title: Soluble vegfr-1 variants for diagnosis of preeclampsia May. 24, 2016
  • Patent Title: Angiopoietin derived peptides Feb. 09, 2016
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Aug. 18, 2015
  • Patent Title: Compositions and methods for treatment of drug resistant multiple myeloma Apr. 07, 2015
  • Patent Title: Bioactive peptides and methods of using same Mar. 24, 2015
  • Patent Title: Method of treating an ischemia-reperfusion injury-related disorder by administering gpcr ligands Sep. 09, 2014
  • Patent Title: Clusterin derived peptide Nov. 05, 2013
  • Patent Title: Angiopoietin derived peptides Sep. 10, 2013
  • Patent Title: Gp96 derived peptides Aug. 20, 2013
  • Patent Title: Bioactive peptides and methods of using same Jul. 23, 2013
  • Patent Title: Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics Apr. 09, 2013
  • Patent Title: Peptide ligands for g-protein coupled receptors Jan. 08, 2013
  • Patent Title: Polynucleotides encoding polypeptides and methods using same May. 10, 2011
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer Mar. 15, 2011
  • Patent Title: Peptides which bind to g protein-coupled receptors Feb. 08, 2011
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis Nov. 30, 2010
  • Patent Title: Hepatocyte growth factor receptor splice variants and methods of using same Jul. 20, 2010
  • Patent Title: Human thrombospondin polypeptide Jun. 29, 2010
  • Patent Title: Diagnostic markers, especially for in vivo imaging and assays and methods of use thereof Jun. 22, 2010
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease May. 11, 2010
  • Patent Title: Hepatocyte growth factor receptor splice variants and methods of using same Mar. 16, 2010
  • Patent Title: Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer Feb. 23, 2010
  • Patent Title: Variants of human glycoprotein hormone alpha chain: compositions and uses thereof Feb. 02, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CGEN in WallStreetBets Daily Discussion

CGEN News

Recent insights relating to CGEN

CNBC Recommendations

Recent picks made for CGEN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CGEN

Corporate Flights

Flights by private jets registered to CGEN